<DOC>
	<DOCNO>NCT00689910</DOCNO>
	<brief_summary>This study evaluate pharmacokinetic disposition raltegravir pregnant HIV-1 infected woman . These result compare pharmacokinetic data obtain follow pregnancy well study previously carry nonpregnant woman male patient . By determine disposition characteristic specific patient population , antiretroviral ( ARV ) dose optimized pregnancy . Appropriate dose necessary minimize adverse effect , slow progression disease , reduce risk vertical transmission . Data also obtain genital tract penetration placenta transfer raltegravir newborn . The subject enrol study take antiretroviral base regimen contain raltegravir twice daily pregnancy . The specific regimen choose primary care provider base antiretroviral history resistance test . They undergo series blood sample pharmacokinetic analysis 12 hour two occasion ; ) 3rd trimester b ) approximately 3 month postpartum . Concentrations raltegravir infant assess cord infant blood sample delivery blood sample approximately 3 month age . Hypothesis : The pharmacokinetic exposure raltegravir measure 12 hour area plasma concentration versus time curve ( AUC0-12h ) third trimester pregnancy similar AUC0-12h estimate three month post-partum .</brief_summary>
	<brief_title>Pharmacokinetics Raltegravir During Third Trimester Pregnancy Post-Partum</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Female , 16 year old old Pregnant , least 14 week gestation order initiate raltegravir treatment decide pregnancy health care provider . The first pharmacokinetic study visit occur sooner 26 week gestation ( 3rd trimester ) Normal fetal heart motion ultrasound , vital sign brief physical exam conduct primary pregnancy health care provider within two week study entry ( part standard prenatal care ) Intolerance resistance least two class antiretroviral agent Availability raltegraviroptimized background regimen base refer provider 's selection resistance test English Spanish speaking Inability follow study protocol drug administration Women plan breastfeed ( recommend HIVinfected woman reduce HIV transmission baby ) Women unable sign inform consent Women history anaphylaxis life threaten adverse event associate antiretroviral therapy</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>pregnancy</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>HIV</keyword>
	<keyword>antiretroviral</keyword>
	<keyword>Treatment HIV pregnant woman Raltegravir</keyword>
</DOC>